Cytek Biosciences earnings date
Cytek Biosciences (8EQ) Q3 2026 Earnings Report
DE:8EQ Q3 2026 EPS Results
- Actual EPS
- -EUR 0.01
- Consensus EPS
- -EUR 0.06
- Beat/Miss
- Beat by +EUR 0.05
- One Year Ago EPS
- EUR 0.00
DE:8EQ Q3 2026 Revenue Results
- Actual Revenue
- EUR 47.66M
- Expected Revenue
- EUR 47.50M
- Beat/Miss
- Beat by +EUR 162.95K
- YoY Revenue Growth
- +1.79%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/04/2026
- Time
- After Close
- Conference Call
- Wednesday, November 4, 2026
Cytek Biosciences's next earnings date is estimated for March 4, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
The call was generally positive. Cytek delivered modest overall revenue growth, strong U.S. and high-end analyzer performance, robust academic and government demand, double-digit service growth, significant gross-margin expansion, and continued investment in new products and recurring revenue. These strengths were partly offset by a 25% APAC revenue decline, a 17% decline in biopharma, distributor and CRO revenue, lower product revenue, higher operating expenses, a lower adjusted EBITDA result, a larger GAAP net loss, and ongoing patent litigation. Management nevertheless reiterated full-year revenue guidance, expects a strong seasonal fourth quarter and anticipates around-breakeven full-year adjusted EBITDA.
Cytek is maintaining the midpoint of its full year 2026 revenue guidance while narrowing the range to $208 million to $211 million, assuming no change from current currency exchange rates; fourth-quarter revenue is expected to be meaningfully higher than third-quarter revenue, consistent with normal seasonality, with service revenue continuing at similar rates to recent quarters and product revenue making up the balance. Full year 2026 adjusted EBITDA is expected to be around breakeven, with adjusted EBITDA anticipated to improve meaningfully in the fourth quarter as revenue increases and legal expenses decline by $3 million to $4 million compared to Q3. The company will provide more specific 2027 guidance when it announces Q4 revenue in late February, early March, but expects to outgrow the market and outgrow its peers, expects improving profitability, and has the Borealis analyzer with full imaging capability slated for launch in 2027.
- Third-Quarter Revenue GrowthThird-quarter revenue was $53.2 million, an increase of 2% year-over-year, in line with prior expectations. Management reiterated the midpoint of full-year 2026 revenue guidance while narrowing the range to $208 million to $211 million.
- Strong U.S. PerformanceU.S. revenue grew 12% year-over-year to $30.4 million, driven by continued strong demand for high-end full spectrum profiling instruments, instrument sales to academic and government customers, and continued service growth. U.S. instrument revenue grew 9%.
- High-End Analyzer GrowthRevenue from the Aurora, Aurora EVO and Borealis category grew more than 30%. Combined Aurora and Aurora EVO placements increased 23% year-over-year, with EVO placements nearly doubling year-over-year. High-end full spectrum profiling instrument revenue grew 11%.
- Instrument Installations and Installed Base ExpansionCytek added 140 instruments during the quarter, bringing the total installed base to 4,073 units.
- Academic and Government Customer StrengthRevenue from academic and government customers increased 38% year-over-year to $24.5 million, with strength across all regions. In the U.S., instrument revenue from this end market grew more than 60%.
- Service Revenue GrowthService revenue grew 13% year-over-year, driven by growth in the installed base and continued active utilization of Cytek systems. Management said service revenue has grown fairly consistently and is expected to continue growing at rates similar to recent quarters.
- Improved Gross MarginGAAP gross profit was $31.2 million, with gross margin of 59% compared to 53% in Q3 2025, an increase of nearly 600 basis points. Product gross margin increased 770 basis points to 61%, while service gross margin increased to 53% from 51%.
- Manufacturing and Cost BenefitsGross margin benefited from lower overhead costs following the completion of the transfer of manufacturing capacity from Seattle to Singapore, as well as lower material costs and lower tariffs. Management said the transfer provides lower-cost manufacturing capacity, greater supply flexibility and helps mitigate tariff-related cost pressures.
- Recurring Revenue ExpansionCombined service and reagent revenue was $19.1 million in Q3 2026 and represented 36% of last-12-month revenue, up from 33% for the 12 months ended September 30, 2025. Management expects recurring revenue to represent an increasing percentage of total revenue over time.
- Cytek Cloud User Growth and Product LaunchCytek launched a new Cytek Cloud analysis tool that integrates the flow cytometry workflow from panel design through data analysis. The total Cytek Cloud user base was approaching 30,000 at the end of the quarter, up more than 20% since the start of the year.
- Borealis Early Access ExpansionBorealis received strong interest from academic and biopharma customers, and the company doubled the size of its early access program during Q3. Borealis has demonstrated 60-color performance, supports nanoparticle analysis and higher sampling rates, and is planned for broader commercial launch in fiscal year 2027 with integrated imaging capabilities.
- Positive Market EnvironmentManagement said market growth has been better from the fourth quarter of the prior year through the first three quarters of 2026, with earlier headwinds having abated. The company characterized the market environment as generally positive.
- 2027 Growth and Investment OutlookAlthough specific 2027 guidance was not provided, management expects to outgrow the market and its peers. The company plans to continue investing in its high-end product portfolio, bring Borealis with full imaging capability to market in 2027, and invest substantially in low- to mid-range instruments and reagents.
- Expected Fourth-Quarter ImprovementManagement expects fourth-quarter revenue to be meaningfully higher than third-quarter revenue, consistent with normal seasonality, driven by typical customer year-end purchasing patterns and continued service growth. Adjusted EBITDA is expected to improve meaningfully in Q4, and full-year adjusted EBITDA is expected to be around breakeven.
- Strong Balance SheetCash, cash equivalents, restricted cash and marketable securities totaled $256 million as of September 30, 2026, compared to $262 million as of June 30, 2026. Management said the balance sheet provides financial flexibility to invest in global growth priorities.
- Patent Litigation PositionA Delaware jury found in Cytek's favor on 3 of 4 asserted claims on both infringement and invalidity. Cytek filed post-trial motions and intends to pursue available legal remedies. Management stated that the verdict does not require changes to the company's product offering or operations and does not affect its ability to sell and ship products.
- Supply Availability for Key ProductsManagement said that, other than small amounts, the company generally books and ships everything within the same quarter. Production rates for Borealis and Aurora EVO systems with enhanced automation capabilities are continuing to increase, and management said supply constraints are not a major issue.
- Organizational Structure PlanningCytek postponed implementation of its new business-unit structure until the start of 2027, while continuing to build teams and focus resources on clinical and solution-focused instruments and reagents.
DE:8EQ Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 04, 2027 | 2026 (Q4) | 0.00- | -0.3 | ― | ― |
| Nov 04, 2026 | 2026 (Q3) | -0.06-0.01 | 0 | -425.00% (-0.02) | |
| Aug 05, 2026 | 2026 (Q2) | -0.08-0.08 | -0.04 | -125.00% (-0.04) | |
| May 07, 2026 | 2026 (Q1) | -0.08-0.13 | -0.08 | -66.67% (-0.05) | |
| Feb 26, 2026 | 2025 (Q4) | -0.02-0.30 | 0.11 | -380.99% (-0.41) | |
| Nov 05, 2025 | 2025 (Q3) | -0.030.00 | 0.06 | -93.65% (-0.05) | |
| Aug 06, 2025 | 2025 (Q2) | -0.04-0.04 | -0.02 | -53.85% (-0.01) | |
| May 08, 2025 | 2025 (Q1) | -0.03-0.08 | -0.01 | -1185.71% (-0.07) | |
| Feb 27, 2025 | 2024 (Q4) | 0.090.11 | 0.08 | 34.44% (+0.03) | |
| Nov 05, 2024 | 2024 (Q3) | 0.010.06 | -0.01 | 887.50% (+0.06) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
